Building Collaborative Heart Failure Care Through a Community Pharmacy Certificate Program and Community Pharmacist-Physician Network Authors: Kazuhiko Kido, Amber Conrad, Ryan Vilain, Tara Bess McNabb, Krista Capehart, Gretchen Garofoli, William Lewis, David Tingler, George Sokos Published: 2026 ABSTRACT AbstractBackgroundLimited evidence exists on the implementation of community-based heart failure (HF) care with community pharmacists.ObjectivesThe goal of the pilot study was to evaluate the impact of collaborative HF care through the development of a community pharmacy certificate program and new partnerships between community pharmacists and providers.MethodsThe pilot project was a 1-year prospective cohort study. Community pharmacists were educated through the certificate program. The patient inclusion criteria were adult patients with HF. Community pharmacists provided patients with comprehensive education about HF medication, HF self-care, diet, and vaccine at enrollment. Pharmacist interventions included: 1) guideline-directed medical therapy optimization; 2) medication education; 3) HF self-care education; 4) adherence optimization; 5) cost mitigation strategies; 6) managing medications worsening HF; 7) immunizations; and 8) dietary education. Each patient was prospectively followed for 6 months.ResultsThree pharmacies were selected as pilot sites. Following completion of the certificate course, all 3 pharmacists passed the exam achieving above 80% on their first attempt. A total of 34 patients were enrolled in the study. All patients received comprehensive education at the initial follow-up encounter with community pharmacists. A total of 80 interventions were performed, of which 30 (37.5%) were accepted. The most accepted intervention was a vaccine (13 patient-accepted interventions), followed by seven accepted adherence-related interventions, five HF guideline-directed medical therapy interventions, 3 nonsteroidal anti-inflammatory drug discontinuation interventions, and two cost-mitigation strategy interventions.ConclusionsThe development and implementation of a HF community pharmacy certificate program prepared 3 community pharmacists to participate in collaborative HF care with cardiology providers. Certified pharmacists delivered comprehensive education to patients with HF and provided a wide range of clinical interventions supporting the potential role of community pharmacists in HF management.Key words: certificate, community, heart failure, implementation, network, pharmacist Background The estimated prevalence of heart failure (HF) in the United States is 6.7 million and it is predicted to increase to 10.3 million in 2040.1 Contemporary medications, devices, and other medical interventions have demonstrated the capability to significantly improve mortality for HF patients.2 However, this led to HF care disparities, particularly in rural and underserved communities, where access to HF specialists and thus optimal therapies may be limited. A meta-analysis demonstrated that patients living in rural areas had a significantly higher risk of mortality in patients with HF compared with those living in urban areas.3 West Virginia (WV) is the third most rural state in the nation; 51.8% of residents live in rural areas.4 To overcome these health disparities, WV University (WVU) Medicine Heart Vascular Institute’s advanced HF clinic currently provides medically underserved HF populations with comprehensive HF care throughout the Appalachian regions. HF pharmacists are integrated into the multidisciplinary HF team to optimize HF medications under collaborative practice agreements with cardiologists. Previously reported data revealed a lack of achievement in pharmacoequity for HF care in WV.5 Over the last decade, pharmacist-led clinical services have improved adherence rates to national guideline-recommended medications in the HF population and can play a pivotal role in addressing the underutilization of the HF guideline-recommended medications.6,7 Community pharmacists are nationally recognized as “the most accessible health care providers” in the United States, and patients visit community pharmacies at least twice as often as primary care offices. However, community pharmacists are underutilized for HF care in rural regions. Community pharmacies could also serve as key team members in HF medication stewardship, supporting appropriate HF care and collaborating with local cardiology offices. However, limited evidence exists for implementing community-based HF care with community pharmacists. One feasibility pilot study evaluated the use of a six-item symptom screening tool to identify patients developing worsening HF.8 Another study with 10 patients after hospitalization for HF showed the potential that community pharmacists can provide in-home medication teaching service.9 However, none characterized community pharmacist pharmacotherapy interventions. In addition, no active HF community pharmacy certificate program was available to ensure community pharmacists’ competency in HF care. Thus, our institution recently developed and launched the Accreditation Council for Pharmacy Education (ACPE)-certified HF certificate program, which was managed by the WVU School of Pharmacy Continuing Education Office. Three community pharmacists completed the course for the pilot project. We also developed a local collaborative network of HF community pharmacists and providers to achieve pharmacoequity for optimal HF therapy in medically underserved areas. As part of this network, 3 community pharmacies were partnered with local cardiology offices for collaborative care after community pharmacists were certified using the original HF community pharmacy certificate program. Objective The objectives of the pilot project were to evaluate the impact of the HF community pharmacy certificate program and new partnerships between community pharmacists and cardiology providers and to characterize community pharmacists’ interventions on HF management with these new initiatives. Methods Community pharmacy heart failure certificate program This 8-hour certificate program mainly outlines 3 categories: 1) HF general contents and guideline-directed medical therapy (GDMT); 2) community pharmacy HF toolkits; and 3) HF transitions of care (Supplemental Table 1). These 3 topics were covered asynchronously via recordings to improve access for local communities. The certificate program contents were developed in accordance with the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) HF guidelines.2 Preknowledge- and postknowledge-based exams were administered before and after the certificate program, with different but paired 30 multiple-choice exam questions from the same 30 key categories according to the ACC/AHA/HFSA HF guidelines (Supplemental Table 2).2 Once community pharmacists scored more than 80% on the exam, they were qualified for a synchronous remote live discussion session to focus on the application of knowledge from the recordings in actual patient care settings. Remote delivery of the session was selected to improve access to the certificate program and accommodate the needs of local community pharmacists. In the live discussion, the primary investigator as a HF pharmacist reviewed key content from recordings and answer keys for the knowledge exam. Then, community pharmacists watched several mock interviews between patients and pharmacists in common clinical scenarios and discussed appropriate interactions and responses to these scenarios (Supplemental Table 3). These hours were accredited by the ACPE. West Virginia heart failure community pharmacist-physician network Once community pharmacists were certified through the ACPE-accredited HF community pharmacy certificate program, the pilot project paired 3 pharmacists with 3 local cardiology services in each community. Specifically, WVU Medicine Heart Vascular Institute identified local cardiologists and advanced practice providers and organized individual meetings between the community pharmacists and the cardiology providers in each community. Community pharmacists were granted access to electronic medical records for patients with HF through local cardiology services. Each collaboration was tailored to community needs. Contact information for the clinics was shared with community pharmacists, and community pharmacists were encouraged to communicate with local cardiology services regularly to stimulate collaboration. Community pharmacists were compensated to participate in the pilot study. Pilot project The pilot project was a 1-year prospective cohort, evidence-based implementation feasibility study evaluating the impacts of the HF community pharmacist-physician network and the HF certificate program. The inclusion criteria were patients with HF aged 18 years or older who presented to the community pharmacies from December 2024 until June 2025. Opportunistic screening at community pharmacies was performed to identify patients for enrollment in the study. Dialysis patients were excluded. Community pharmacists provided patients with HF medication education, self-care education (eg, daily vital and weight checks), dietary education (all pharmacists watched the educational recording and the handout developed by the HF clinical dietician), and vaccine education/screening at enrollment. The study collected baseline characteristics and pharmacist interventions: 1) GDMT optimization; 2) medication education; 3) self-care education; 4) adherence optimization; 5) cost mitigation strategies; 6) managing medications worsening HF; 7) immunizations; and 8) dietary education (defined in Table 1). Community pharmacists provided recommendations to physicians and advanced practice practitioners in-person or by phone. Community pharmacists did not practice under collaborative practice agreements. Acceptance rates of interventions by physicians/advanced practice providers or patients were collected separately. Each patient was prospectively followed for 6 months. There were no scheduled follow-up visits with pharmacists during the follow-up. At the end of the 6-month follow-up, pharmacists attempted to interview patients about their medication history, and each patient completed satisfaction surveys about medication or dietary education at the initial visit and about their experiences in community pharmacies during the 6-month follow-up. If patients refused to visit the pharmacies at the 6-month follow-up, medication data were obtained from the electronic medical record. As exploratory outcomes, hospitalization for HF and all-cause hospitalization were collected at 6-month follow-up. This evidence-based implementation project was approved by the WVU Institutional Review Board. Table 1Definition of Community Pharmacist Interventions and Time Required for Each InterventionInterventionDefinitionExampleTime per Intervention (Minutes) (Sample Size)GDMT optimizationRecommend initiating, modifying (dose reduction/increase), or discontinuing guideline-recommended medications for heart failureInitiate spironolactone for heart failure with reduced ejection fraction20.0 ± 8.5 (n = 8)Mediation educationEducate on indications, dosing, adverse drug effects, monitoring, cost, and storage, and labs if neededN/A7.6 ± 4.8 (n = 34)Self-care educationEducate on daily vital and weight check, and worsening HF symptomsCheck blood pressure and heart rate using a validated blood pressure cuffs daily6.8 ± 3.7 (n = 34)Addressing the adherence issueAssess adherence status using refill history from community pharmacies and recommend solutions to improve nonadherence.Patients filled the sacubitril/valsartan prescription late. Patient enrolled in the medication synchronization program to receive all medications at the same time each month. Patient reports issues with remembering medications daily. Reviewed standard solutions to aid in medication adherence including a pill box, alarm, placing in a commonly viewed area of home, etc. The patient was also notified the pharmacy offers free medication adherence packaging.9.0 ± 4.9 (n = 7)Cost mitigation strategiesOffer resources to improve access to heart failure medications such as copay-cards, patient assistance program, and free-trial cardsThe patient is interested in starting SGLT2i therapy however all agents on the patient's insurance plan are tier 3 and are not cost-effective. We reached out to a patient advocate through the cardiology office requesting enrollment in financial assistance programs.10 (variance cannot be estimated with 2 cases) (n = 2)Managing medications worsening HFRecommend stopping medications worsening HF to providers and patientsRecommend stopping ibuprofen in patients with heart failure6.7 ± 2.9 (n = 3)Vaccine educationAt the initial visit, screen eligible vaccines especially important to prevent hospitalization for HFN/A5.7 ± 2.9 (n = 34)ImmunizationDiscuss the eligibility of vaccines with patients and potential benefits. If eligible and patients agree, administer vaccinesRecommend initiating and administering the RSV vaccine in 70-year-old patient with heart failure8.2 ± 4.1 (n = 60)Dietary educationEducate on dietary modification with HF dietary handouts developed by HF clinical dieticianN/A6.5 ± 3.4 (n = 34)Values are mean ± SD.GDMT = guideline-directed medical therapy; HF = heart failure; N/A = not applicable; RSV = respiratory syncytial virus; SGLT2i = sodium glucose co-transporter 2 inhibitor. Definition of Community Pharmacist Interventions and Time Required for Each Intervention Values are mean ± SD. GDMT = guideline-directed medical therapy; HF = heart failure; N/A = not applicable; RSV = respiratory syncytial virus; SGLT2i = sodium glucose co-transporter 2 inhibitor. Statistical analysis Data was displayed as mean ± SD, median (range or interquartile), and count (percentage). A descriptive analysis was performed to characterize the cohort’s baseline and outcomes at 6-month follow-up. Patient satisfaction was evaluated using a Likert scale ranging excellent to poor. Semistructured interviews with participating community pharmacists were performed to elicit facilitators and barriers following completion of the pilot study. No imputation was performed for missing data. Participants who lost to follow-up were excluded from 6-month follow-up analyses such as patient satisfaction. SPSS (IBM, version 29.0.2) was used to perform all statistical analyses. Results Heart failure certificate precourse and postcourse knowledge exam Compared with the precourse scores, the postcourse scores were numerically higher for all 3 pharmacists. All 3 pharmacists scored above 80% in their first attempt and passed the course (Figure 1). Across the eight domains, numerical improvement in postcourse scores was observed in 5 domains: 1) HF identification and pathophysiology; 2) HF GDMT; 3) acute decompensated HF; 4) medications worsening HF; and 5) comorbidity management (Supplemental Table 4). All 3 pharmacists achieved perfect scores in the domain of cost mitigation strategies at both the precourse and postcourse exams. Two of the 3 pharmacists demonstrated lower postcourse exam scores in the domains of patient education, adherence, and prevention. In the domain of diuretic and volume/electrolyte management, 1 pharmacist achieved perfect scores on both precourse and postcourse exams. In contrast, another pharmacist demonstrated a lower postcourse score but the other pharmacist achieved a perfect postcourse exam score in the domain. Community Pharmacist Heart Failure Certificate Pre- and Post-Course Scores Baseline patient characteristics A total of 34 patients were enrolled in the study (Table 2). The mean age was 65.2 ± 12.1 years with 20 (58.8%) males and 21 (61.8%) Caucasian patients. Twenty-seven patients were Medicare beneficiaries (79.4%), whereas 7 (20.6%) and 24 (70.6%) patients were followed by HF-specialist and general cardiology providers, respectively. The mean left ventricular ejection fraction (EF) was 47.7% ± 15.5%. The common HF type was HF with preserved EF (HFpEF) (35.3%), followed by HF with reduced EF (HFrEF) (29.4%) and HF with mildly reduced EF (HFmrEF) (14.7%). The mean creatinine (1.04 ± 0.31 mg/dL), potassium (4.12 ± 0.49 mEq/L), systolic blood pressure (122.3 ± 16.3 mm Hg), and heart rate (73.7 ± 11.0 beats/min) were within the normal range in the cohort. The mean body mass index was 32.3 ± 5.5 kg/m2. Table 2Baseline Characteristics of Included Patients (N = 34)Age, years65.2 ± 12.1Male20 (58.8)Race/ethnicity White21 (61.7) Black or African American1 (2.9) Unknown12 (35.3)West Virginia University Medicine patient32 (94.1)Type of insurance Medicare27 (79.4) WV Medicaid5 (14.7) Commercial1 (2.9) Uninsured1 (2.9)Patient care service HF cardiology7 (20.6) General cardiology24 (70.6) Primary care2 (5.9) Unknown1 (2.9)Rural residencec, %10 (30.3)Ejection fraction, %47.7 ± 15.5Types of cardiomyopathy, % Ischemic cardiomyopathy10 (29.4) Nonischemic cardiomyopathy6 (17.6) Mixed cardiomyopathy3 (8.8) Unknown15 (44.1)Types of HF Heart failure with reduced ejection fraction10 (29.4) Heart failure with mildly reduced ejection fraction5 (14.7) Heart failure with preserved ejection fraction12 (35.3) Unknown7 (20.6)Implantable cardioverter defibrillator6 (17.6)Cardiac resynchronization therapy1 (2.9)Estimated glomerular filtration rate, mL/min/1.73 m268.5 ± 17.7Sodium, mEq/L138.1 ± 5.2Creatinine, mg/dL1.04 ± 0.31Potassium, mEq/L4.12 ± 0.49Systolic blood pressure, mm Hg122.3 ± 16.3Heart rate, beats/min73.7 ± 11.0Weight, kg95.4 ± 22.7Height, cm179.9 ± 73.2Body mass index, kg/m232.3 ± 5.5NYHA functional class I3 (8.8) II12 (35.3) III1 (2.9) IV1 (2.9) Unknown17 (50.0)Hypertension31 (91.2)Diabetes19 (55.9)Dyslipidemia29 (85.3)Atrial fibrillation15 (44.1)History of acute coronary syndrome or coronary artery disease17 (50.0)Angiotensin receptor neprilysin inhibitor (ARNI)10 (66.7)a 24/26 mg twice daily6 (60.0) 49/51 mg twice daily2 (20.0) 97/103 mg twice daily2 (20.0)ACEI/ARB/ARNI29 (85.3)Beta-blocker14 (93.3)aMetoprolol succinate equivalent dose (range) (mg/day)50 (12.5-300)aSpironolactone or eplerenone8 (53.3)aSpironolactone equivalent dose, mg/day25 (12.5-50)aSGLT2i14 (41.2)bLoop diuretic13 (38.2)Furosemide equivalent dose, mg/day40 (20-160)Thiazide diuretic3 (8.8)Medications worsening HFd3 (8.8)NSAID use3 (8.8)ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; NSAID = non-steroidal anti-inflammatory drug; WV = West Virginia; other abbreviations as in Table 1.Values are n (%), mean ± SD, or median (range).aOnly heart failure with reduced or mildly reduced ejection fraction (n = 15).bInclude all types of heart failure.cn = 33 (1 patient missing zip code). 2020 rural-urban commuting area codes were used to delineate rural and urban areas.dPioglitazone, cilostazol, flecainide, propafenone, dronedarone, itraconazole oral for HFrEF or HFmrEF, prednisone long-term chronic use (not counting short term therapy), diltiazem for HFrEF or HFmrEF, verapamil for HFrEF or HFmrEF, and disopyramide for HFrEF or HFmrEF. Baseline Characteristics of Included Patients (N = 34) ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; NSAID = non-steroidal anti-inflammatory drug; WV = West Virginia; other abbreviations as in Table 1. Values are n (%), mean ± SD, or median (range). Only heart failure with reduced or mildly reduced ejection fraction (n = 15). Include all types of heart failure. n = 33 (1 patient missing zip code). 2020 rural-urban commuting area codes were used to delineate rural and urban areas. Pioglitazone, cilostazol, flecainide, propafenone, dronedarone, itraconazole oral for HFrEF or HFmrEF, prednisone long-term chronic use (not counting short term therapy), diltiazem for HFrEF or HFmrEF, verapamil for HFrEF or HFmrEF, and disopyramide for HFrEF or HFmrEF. Baseline heart failure medications at enrollment Ten of 15 (66.7%) patients with HFrEF or HFmrEF were receiving angiotensin receptor neprilysin inhibitors (ARNI), and 14 (93.3%) patients were receiving beta-blockers (BBs) (Table 2). Eight of the 15 (53.3%) patients with HFrEF or HFmrEF were on spironolactone or eplerenone. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) was used in 14 of 34 (41.2%) patients with any HF, with use at 8.3% in patients with HFpEF and 73.3% in patients with HFrEF or HFmrEF. Six of 10 (60.0%) patients receiving sacubitril/valsartan were on 24/26 mg doses, and the median metoprolol succinate equivalent dose was 50 mg/day (range: 12.5-300). Community pharmacist interventions All included patients received HF medication education, self-care education, dietary education, and vaccine education/screening, which took a mean of 26.3 ± 12.0 minutes during the initial follow-up encounter with community pharmacists. A total of 80 interventions were performed, of which 30 (37.5%) were accepted (Table 3). The most commonly accepted intervention was vaccination (13 interventions accepted by patients), followed by seven adherence-related interventions, five HF GDMT interventions, 3 nonsteroidal anti-inflammatory drug (NSAID) discontinuation interventions, and two cost-mitigation strategy interventions. The details of the vaccine interventions are summarized in Table 4. Table 3The Summary of Community Pharmacist InterventionsPharmacist InterventionInterventions Attempted, n (%)Intervention Accepted, n/Sample Size (%)Total8030/80 (37.5)Vaccine60 (75.0)13/60 (21.7) (by patients)GDMT8 (10.0)5/8a (62.5) (by providers)Addressing adherence7 (8.8)7/7 (100)NSAID education3 (3.8)3/3 (100)Cost mitigation strategies2 (2.5)2/2 (100)Abbreviations as in Tables 1 and 2.aThree cases of 5 provider-approved interventions were declined by patients (2 patients declined the use of SGLT2i—1 due to concern for urinary tract infection and the other due to general concerns about adverse drug events; 1 patient declined spironolactone initiation [reason not available]). The Summary of Community Pharmacist Interventions Abbreviations as in Tables 1 and 2. Three cases of 5 provider-approved interventions were declined by patients (2 patients declined the use of SGLT2i—1 due to concern for urinary tract infection and the other due to general concerns about adverse drug events; 1 patient declined spironolactone initiation [reason not available]). Table 4Vaccine InterventionsVaccineRecommendedAccepted by Patients, n (%)All vaccines6013 (21.7)COVID-19141 (7.1)RSV185 (27.8)Shingles52 (40.0)Pneumonia172 (11.8)Influenza31 (33.3)Tdap22 (100)Hepatitis B10Abbreviation as in Table 1. Vaccine Interventions Abbreviation as in Table 1. Medication regimens at baseline and 6-month follow-up are summarized in Table 5. The ARNI use and dose remained unchanged over 6 months, whereas the BB, spironolactone, and SGLT2i use were nominally decreased at 6-month follow-up encounters. Table 5Heart Failure Medication Use and Dose at Baseline and 6 MoHeart Failure MedicationBaseline (n = 34)6 months (n = 34)ARNI, n (%)a10 (66.7)b10 (66.7)b 24/26 mg twice daily6 (60.0)6 (60.0) 49/51 mg twice daily2 (20.0)2 (20.0) 97/103 mg twice daily2 (20.0)2 (20.0)ACEI/ARB/ARNI, n (%)29 (85.3)27 (79.4)Beta-blocker, n (%)14 (93.3)b11 (73.3)bMetoprolol succinate equivalent dose, median (range), mg/day50 (12.5-300)25 (12.5-150)bSpironolactone or eplerenone, n (%)8 (53.3)b6 (40.0)bSpironolactone equivalent dose, median (range), mg/day25 (12.5-50)25 (12.5-25)bSGLT2i, n (%) All types of HF14/34 (41.2)c9/34 (26.5) HFrEF or HFmrEF11/15 (73.3)7/15 (46.7) HFpEF1/12 (8.3)0/12 (0.0) Types of HF not documented2/7 (28.6)2/7 (28.6)Loop diuretic, n (%)13 (38.2)13 (38.2)Furosemide equivalent dose, mg/day, median (range)40 (20-160)40 (20-80)Thiazide diuretic, n (%)3 (8.8)0Medications worsening HF, n (%)3 (8.8)Not collectedNSAID use, n (%)3 (8.8)Not collectedARNI = angiotensin receptor neprilysin inhibitor; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; other abbreviations as in Tables 1 and 2.aThe percentage for each dose is based on 10 patients receiving ARNI.bOnly HFrEF or HFmrEF (n = 15).cInclude all types of HF. If only HFrEF or HFmrEF, 73.3%. If HFpEF, only 8.3%. Heart Failure Medication Use and Dose at Baseline and 6 Mo ARNI = angiotensin receptor neprilysin inhibitor; HFmrEF = heart failure with mildly reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; other abbreviations as in Tables 1 and 2. The percentage for each dose is based on 10 patients receiving ARNI. Only HFrEF or HFmrEF (n = 15). Include all types of HF. If only HFrEF or HFmrEF, 73.3%. If HFpEF, only 8.3%. Patient satisfaction survey and hospitalization A total of 26 patient (20 patients from the pharmacy A; 2 patients from the pharmacy B; and 4 patients from the pharmacy C) satisfaction surveys were submitted at 6-month follow-up encounters (Table 6). Overall, more than 80% rated excellent or very good on all survey questions. Overall experiences with community pharmacists were rated either excellent or very good by 24 of 26 (92.3%) of included patients. No patients were hospitalized for HF, but 6 (17.6%) experienced hospitalization for any cause during the 6-month follow-up period. Table 6Patient Satisfaction Survey Results (n = 26)Survey QuestionExcellentVery GoodGoodFairPoorAre you satisfied with waiting time before seeing the pharmacist?13 (50.0)11 (42.3)2 (7.7)00Rate length of time you spent with the pharmacist11 (42.3)11 (42.3)4 (15.4)00Rate the information about your heart failure medications you received from the pharmacist14 (53.8)10 (38.5)1 (3.8)1 (3.8)0Rate the medical information about heart failure you received from the pharmacist13 (50.0)8 (30.8)5 (19.2)00Rate the self-care information about your heart failure you received from the pharmacist14 (53.8)8 (30.8)4 (15.4)00Rate the information about vaccines for your heart failure you received from the pharmacist15 (57.7)10 (38.5)1 (3.8)00Rate your experience with your pharmacist overall over 6 months17 (65.4)7 (26.9)2 (7.7)00Rate the information on the heart healthy diet that you received.14 (53.8)9 (34.6)3 (11.5)00Rate your confidence in your ability to identify high sodium foods.9 (34.6)12 (46.2)5 (19.2)00Rate your confidence in your ability to make heart healthy diet changes.9 (34.6)15 (57.7)2 (7.7)00Values are n (%). Patient Satisfaction Survey Results (n = 26) Values are n (%). Implementation feedback from community pharmacists Semistructured interviews with 2 participating community pharmacists identified several implementation themes. Pharmacists reported that workflow integration was feasible and electronic medical record access supported timely comprehensive medication review of HF regimens. Participating pharmacists also stated positive work relationships with collaborating providers. They noted that competing demands during the Medicare open enrollment period or staffing shortages limited available time for delivery of the study-related clinical services, which may have reduced opportunities for enrollment and follow-up. In addition, pharmacists identified program visibility as the primary opportunity for improvement. They suggested clearer referral pathways could enhance patient enrollment and engagement in the statewide implementation. Discussion The HF community pharmacy certificate program was effective in educating community pharmacists. Community pharmacists provided a comprehensive patient education (HF medication, self-care, dietary, and vaccine education) in an average of 30 minutes, and more than 90% of patients rated their experiences with pharmacists as either excellent or very good in satisfaction surveys. Vaccine interventions were the most common category of interventions, followed by addressing adherence issues, HF GDMT interventions, NSAID discontinuation/minimization interventions, and cost mitigation strategies. The baseline HFrEF GDMT was acceptable; however, mineralocorticoid antagonist (MRA) and SGLT2i use was not optimized. Among HF types, SGLT2i use for HFpEF was remarkably low at 8.3%. The sacubitril/valsartan and BB doses at baseline were also lower compared to the target doses. The sacubitril/valsartan use and dose remained the same, and BB use and dose numerically declined at the follow-up. The use of MRA and SGLT2i uses numerically declined at 6-month follow-up (Central Illustration). Implementing West Virginia Heart Failure Community Pharmacy Certificate And Community Pharmacist-Provider Network: A Pilot Study HF = heart failure; GDMT = guideline-mediated medical therapy; NSAID = non-steroidal anti-inflammatory drug. A multidisciplinary approach to GDMT optimization is more effective than a nonmultidisciplinary one.10 The involvement of pharmacists in HFrEF GDMT management has been shown to be significantly associated with the use of all four GDMT agents and individual GDMT use for HFrEF compared to the care without a pharmacist’s involvement.5 However, it is not realistic for each cardiology and primary care clinic to have a pharmacist physically involved in each institution. Thus, our study proposed a collaborative model to involve HF-certified community pharmacists in HF care within each community. About 5 of 34 patients in our study received provider-accepted GDMT interventions, but 3 separate interventions were rejected by patients, mainly due to concerns for adverse drug events. In particular, perceived risk of the urinary tract infection (UTI) associated with SGLT2i is often cited as a major reason for declining treatment initiation. However, not all clinical trials showed the increased risk of UTI due to SGLT2i.11 The cardiovascular benefits outweighing the risks of UTIs should be fully emphasized when pharmacists counsel patients about SGLT2i. As SGLT2i use declined at 6 months, patients should be informed about the risks of discontinuing SGLT2i due to uncomplicated UTIs, as the study showed that discontinuation was associated with an increased risk of cardiovascular events but not with fewer UTI episodes.12 Community pharmacists can play a significant role in educating patients and providers about the appropriate counseling, careful assessment of risks and benefits, and management of SGLT2i in the setting of UTIs. Focusing on the prioritized interventions is the strategy to increase the number of recommendations accepted by providers in the statewide implementation project. The present study showed 2 significant opportunities for future investigation: 1) underutilization of MRAs for HFrEF and HFmrEF (53.3% at baseline) and SGLT2i for HFpEF (8.3% at baseline); and 2) underdosing of ARNI (60% were receiving 24/26 mg dose and 20% were receiving 49/51 mg dose at baseline and 6-month follow-up) and BB for HFrEF and HFmrEF (metoprolol equivalent median dose/day 50 mg at baseline and 25 mg at 6-month follow-up). Underutilization of MRA and SGLT2i was also observed in our previous community-based telehealth implementation study.7 Our future investigation will greatly broaden this program in WV by developing and implementing the simplified initiation criteria to start MRA and SGLT2i for all eligible patients. Once patients meet the criteria, community pharmacists can recommend them to collaborating providers to minimize clinical inertia and standardize care. To overcome the clinical inertia for underdosing of ARNI and BB, the statewide implementation project will also develop the criteria for dose titration recommendations. If patients meet the criteria for ARNI and BB, community pharmacists recommend dose increases and follow-up labs/vital monitoring plan to HF providers. These recommendations will be also communicated to providers in a standardized manner during the statewide implementation of the project. The present study also showed concern about GDMT persistence over 6 months, as reflected in declining uses of BB, MRA, and SGLT2i. The multinational HF registry, EVOLUTION registry, also corroborated that the discontinuation rate of MRA was 42.2%, followed by BB at 25.2% and dapagliflozin at 23.5% within 12 months from initiation.13 Community pharmacists have access to refill history in their pharmacies and can closely monitor adherence as local gatekeepers. In the statewide implementation, community pharmacists will conduct at least monthly follow-up on adherence assessments to improve persistence with GDMT regimens and will collect refill history to assess persistence of GDMT during the 6-month follow-up. Recommendations for immunizations were the most common category of community pharmacist interventions during the pilot study. Community pharmacists are recognized as experts in vaccine implementation in their communities.14, 15, 16 The ACC consensus statement proposed that adult immunization be incorporated into cardiovascular care, supported by contemporary evidence.17 The ACC/AHA/HFSA HF guidelines also suggest that vaccines against respiratory illnesses are reasonable.3 Major HF clinical trials had previously demonstrated that patients with HF were at a risk of developing pneumonia.18 More remarkably, the first episode of pneumonia was significantly associated with 4-times higher all-cause mortality. However, the U.S. HF registry showed that about 1 in 3 hospitalized patients with HF did not receive influenza or pneumococcal vaccines.19 Influenza vaccines in patients with HF were significantly associated with a reduced risk of all-cause mortality by approximately 20%.20 Another study revealed that influenza vaccines significantly reduced all-cause hospitalizations by 16% and pneumonia by approximately 40% compared with the placebo group.21 Registry data showed that a lack of pneumococcal vaccination was associated with a higher mortality risk and a numerical increase in pneumococcal hospitalizations in community-dwelling patients.22 Recently, the DAN-RSV (a Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein-based Vaccine Effectiveness for Preventing RSV Hospitalization in Adults Aged 60 Years or Above) trial showed that the respiratory syncytial virus (RSV) vaccine significantly reduced the risk of hospitalization for RSV-related respiratory disease compared with the placebo group.23 The prespecified analysis of the trial in the subcohort with HF corroborated that the RSV vaccine was significantly associated with reduced risks of RSV-related cardiopulmonary hospitalizations.24 The use of COVID-19 vaccines was also significantly associated with a reduced risk of all-cause hospitalization and all-cause mortality in patients with HF compared to unvaccinated patients with HF.25 Ensuring the patients are up-to-date with influenza, pneumococcal, RSV, and COVID vaccines should be suggested to providers and will be screened at the initial screening by community pharmacists. Although about 20% of patients accepted and received recommended vaccines at their pharmacies, the majority still rejected them, potentially because the particular benefits of these vaccines for HF care were not well communicated to patients with HF according to available evidence. The revised HF certificate program will incorporate a recorded session that details both the benefits of vaccination and evidence-based strategies to enhance vaccine confidence in patients with HF. The collaboration with primary care teams will be incorporated into the revised collaborative network during the statewide HF community pharmacy-provider collaborative network. The current pilot study was mainly partnered with either HF or general cardiology providers. However, more than 1 in 2 patients with HF is treated solely by primary care providers in general.26 Our previous study showed that academic detailing with primary care providers was feasible and numerically increased the use of BBs and ARNI over the 6-month follow-up, whereas the use of MRA and SGLT2i was not significantly changed.7 Thus, our priority efforts during the statewide implementation with primary care physicians are the initiation and persistence of MRA and SGLT2i. Study limitations The present study is a pilot project with multiple limitations. First, this included patients from 3 sites and was a small-scale study. Thus, the external validity of the main findings needs to be investigated further in a larger-scale study. To address this, we propose developing a statewide HF community pharmacist-provider collaborative network to improve GDMT for medically underserved populations in WV. Second, the present study did not collect the number of patients screened and excluded to investigate nonresponse and selection bias. Third, some patients did not follow up with pharmacists and did not complete follow-up surveys at the end of follow-up. In the statewide implementation study, community pharmacists will follow up with patients at least monthly and investigate the interventions to improve GDMT adherence and persistence. Fourth, the providers’ reasons for declining pharmacist interventions were not collected in the pilot project. The statewide implementation study will collect these reasons and characterize barriers to optimizing GDMT in each community. Fifth, the knowledge exam was not formally validated. However, the pretests and post-tests were paired and constructed as parallel forms using the same content domain blueprint (Supplemental Table 1). Sixth, we observed inconsistent pharmacist performance on the postcourse exam. For example, two of the 3 pharmacists demonstrated lower postcourse exam scores in the domain of patient education, adherence, and prevention. To address this finding, the statewide implementation study will include more detailed education during the on-live session in the domain, where pharmacists demonstrated lower performance based on the postcourse results. Seventh, the survey primarily investigated the subject’s experiences during the initial visit. However, the survey was delivered at the end of the follow-up. Thus, 2 separate surveys (1 for the initial visit and the other for experiences during follow-up) should be delivered to subjects to minimize recall bias during statewide implementation. Eighth, although providers and patients accepted all pharmacist recommendations to avoid NSAIDs, NSAID use was not reassessed at the 6-month follow-up. Therefore, continued avoidance of NSAIDs cannot be confirmed. Lastly, community pharmacists were fiscally incentivized for the present study. Widespread acceptance of the proposed collaborative HF care with HF community pharmacy certificate program would likely need a sustainable reimbursement mechanism. Conclusions The HF community pharmacy certificate program was effective for educating community pharmacists. Almost all patients were satisfied with the community pharmacist’s comprehensive education and service. The most common category of community pharmacy interventions was immunization. About 15% of included patients received provider-accepted interventions (initiation of either MRA or SGLT2i). Adherence issues, NSAID discontinuation/minimization interventions, and cost mitigation strategies were other interventions. COMPETENCY IN MEDICAL KNOWLEDGE: HF certified community pharmacists can provide evidence-based interventions and comprehensive HF education in their communities. COMPETENCY IN PATIENT CARE: A HF pharmacist-provider network can deliver a collaborative HF medication stewardship activity in HF populations. TRANSLATIONAL OUTLOOK: A statewide implementation study should incorporate standardized referral pathways, GDMT initiation/titration criteria, and longitudinal follow-up processes to improve GDMT optimization and persistence. Funding support and author disclosures Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number 5U54GM104942-08. This project was sponsored by a generous donation from Dr Robert J. Powell to the WVU Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Kido is an independent contractor as a topic editor for DynaMed, LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Acknowledgments The authors appreciate the WVU Arthur Jacknowitz Endowment Chair Fund for open access fee payment. The authors would like to acknowledge Dr. Robert J. Powell for his support and generosity. The authors would like to thank Dr. William Petros for reviewing the manuscript. The authors also want to thank Ms. Cynthia Fisher-Duda for the data collection and all of the community pharmacy sites and clinics that participated in the project. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental tables, please see the online version of this paper. Supplementary material Supplemental_Material References Associated Data Supplementary Materials Supplemental_Material